Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results.

Gluz O, Nitz U, Liedtke C, Christgen M, Grischke EM, Forstbauer H, Braun M, Warm M, Hackmann J, Uleer C, Aktas B, Schumacher C, Bangemann N, Lindner C, Kuemmel S, Clemens M, Potenberg J, Staib P, Kohls A, von Schumann R, Kates R, Kates R, Schumacher J, Wuerstlein R, Kreipe HH, Harbeck N.

J Natl Cancer Inst. 2018 Jun 1;110(6):628-637. doi: 10.1093/jnci/djx258.

PMID:
29228315
2.

Lobular carcinoma in situ and invasive lobular breast cancer are characterized by enhanced expression of transcription factor AP-2β.

Raap M, Gronewold M, Christgen H, Glage S, Bentires-Alj M, Koren S, Derksen PW, Boelens M, Jonkers J, Lehmann U, Feuerhake F, Kuehnle E, Gluz O, Kates R, Nitz U, Harbeck N, Kreipe HH, Christgen M.

Lab Invest. 2018 Jan;98(1):117-129. doi: 10.1038/labinvest.2017.106. Epub 2017 Oct 16.

PMID:
29035379
3.

De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel.

Nitz UA, Gluz O, Christgen M, Grischke EM, Augustin D, Kuemmel S, Braun M, Potenberg J, Kohls A, Krauss K, Stefek A, Schumacher C, Forstbauer H, Reimer T, Fischer H, Liedtke C, Wuerstlein R, Schumacher J, Kates R, Kreipe H, Harbeck N; West-German Study Group (WSG)-ADAPT Investigators.

Ann Oncol. 2017 Nov 1;28(11):2768-2772. doi: 10.1093/annonc/mdx494.

PMID:
28945833
4.

De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET.

Harbeck N, Gluz O, Christgen M, Kates RE, Braun M, Küemmel S, Schumacher C, Potenberg J, Kraemer S, Kleine-Tebbe A, Augustin D, Aktas B, Forstbauer H, Tio J, von Schumann R, Liedtke C, Grischke EM, Schumacher J, Wuerstlein R, Kreipe HH, Nitz UA.

J Clin Oncol. 2017 Sep 10;35(26):3046-3054. doi: 10.1200/JCO.2016.71.9815. Epub 2017 Jul 6.

PMID:
28682681
5.

Neoadjuvant therapy for triple negative and HER2-positive early breast cancer.

Harbeck N, Gluz O.

Breast. 2017 Aug;34 Suppl 1:S99-S103. doi: 10.1016/j.breast.2017.06.038. Epub 2017 Jun 27. Review.

PMID:
28666920
6.

Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial.

Nitz U, Gluz O, Christgen M, Kates RE, Clemens M, Malter W, Nuding B, Aktas B, Kuemmel S, Reimer T, Stefek A, Lorenz-Salehi F, Krabisch P, Just M, Augustin D, Liedtke C, Chao C, Shak S, Wuerstlein R, Kreipe HH, Harbeck N.

Breast Cancer Res Treat. 2017 Oct;165(3):573-583. doi: 10.1007/s10549-017-4358-6. Epub 2017 Jun 29.

PMID:
28664507
7.
8.

San Antonio 2016: Progress on the Long Way to Individualized Treatment of Breast Cancer.

Müller V, Gluz O, Pierga JY, Thill M, Rack B, Witzel I.

Breast Care (Basel). 2017 Mar;12(1):54-58. doi: 10.1159/000458749. Epub 2017 Feb 28. No abstract available.

9.

Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression.

Nitz U, Gluz O, Huober J, Kreipe HH, Kates RE, Hartmann A, Erber R, Moustafa Z, Scholz M, Lisboa B, Mohrmann S, Möbus V, Augustin D, Hoffmann G, Weiss E, Böhmer S, Kreienberg R, Du Bois A, Sattler D, Thomssen C, Kiechle M, Jänicke F, Wallwiener D, Harbeck N, Kuhn W.

Ann Oncol. 2017 Nov 1;28(11):2899. doi: 10.1093/annonc/mdw349. No abstract available.

PMID:
27634692
10.

Loss of Dickkopf 3 Promotes the Tumorigenesis of Basal Breast Cancer.

Lorsy E, Topuz AS, Geisler C, Stahl S, Garczyk S, von Stillfried S, Hoss M, Gluz O, Hartmann A, Knüchel R, Dahl E.

PLoS One. 2016 Jul 28;11(7):e0160077. doi: 10.1371/journal.pone.0160077. eCollection 2016.

11.

Lobular breast cancer: Clinical, molecular and morphological characteristics.

Christgen M, Steinemann D, Kühnle E, Länger F, Gluz O, Harbeck N, Kreipe H.

Pathol Res Pract. 2016 Jul;212(7):583-97. doi: 10.1016/j.prp.2016.05.002. Epub 2016 May 5. Review.

PMID:
27233940
12.

Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial.

Gluz O, Liedtke C, Huober J, Peyro-Saint-Paul H, Kates RE, Kreipe HH, Hartmann A, Pelz E, Erber R, Mohrmann S, Möbus V, Augustin D, Hoffmann G, Thomssen C, Jänicke F, Kiechle M, Wallwiener D, Kuhn W, Nitz U, Harbeck N; EC-Doc investigators (West German Study Group/AGO-B).

Ann Oncol. 2016 Jun;27(6):1035-40. doi: 10.1093/annonc/mdw070. Epub 2016 Feb 18.

PMID:
27022068
13.

First-line Bevacizumab-containing Therapy for HER2-negative Metastatic Breast Cancer: Final Results from a Prospective German Study.

Schneeweiss A, Förster F, Tesch H, Aktas B, Gluz O, Geberth M, Hertz-Eichenrode MM, Schönegg W, Schumacher C, Kutscheidt A, Kiewitz C, Klawitter S, Schmidt M.

Anticancer Res. 2016 Mar;36(3):967-74.

PMID:
26976985
14.

The West German Study Group Breast Cancer Intrinsic Subtype study: a prospective multicenter decision impact study utilizing the Prosigna assay for adjuvant treatment decision-making in estrogen-receptor-positive, HER2-negative early-stage breast cancer.

Wuerstlein R, Sotlar K, Gluz O, Otremba B, von Schumann R, Witzel I, Schindlbeck C, Janni W, Schem C, Bauerfeind I, Hasmueller S, Tesch H, Paulenz A, Ghali N, Orujov E, Kates RE, Cowens W, Hornberger J, Pelz E, Harbeck N.

Curr Med Res Opin. 2016 Jul;32(7):1217-24. doi: 10.1185/03007995.2016.1166102. Epub 2016 Mar 30.

PMID:
26971372
15.

BRCA1-like profile predicts benefit of tandem high dose epirubicin-cyclophospamide-thiotepa in high risk breast cancer patients randomized in the WSG-AM01 trial.

Schouten PC, Gluz O, Harbeck N, Mohrmann S, Diallo-Danebrock R, Pelz E, Kruizinga J, Velds A, Nieuwland M, Kerkhoven RM, Liedtke C, Frick M, Kates R, Linn SC, Nitz U, Marme F.

Int J Cancer. 2016 Aug 15;139(4):882-9. doi: 10.1002/ijc.30078. Epub 2016 May 5.

16.

West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment.

Gluz O, Nitz UA, Christgen M, Kates RE, Shak S, Clemens M, Kraemer S, Aktas B, Kuemmel S, Reimer T, Kusche M, Heyl V, Lorenz-Salehi F, Just M, Hofmann D, Degenhardt T, Liedtke C, Svedman C, Wuerstlein R, Kreipe HH, Harbeck N.

J Clin Oncol. 2016 Jul 10;34(20):2341-9. doi: 10.1200/JCO.2015.63.5383. Epub 2016 Feb 29.

PMID:
26926676
17.

Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade.

Müller P, Kreuzaler M, Khan T, Thommen DS, Martin K, Glatz K, Savic S, Harbeck N, Nitz U, Gluz O, von Bergwelt-Baildon M, Kreipe H, Reddy S, Christgen M, Zippelius A.

Sci Transl Med. 2015 Nov 25;7(315):315ra188. doi: 10.1126/scitranslmed.aac4925.

PMID:
26606967
18.

The prognostic impact of age in different molecular subtypes of breast cancer.

Liedtke C, Rody A, Gluz O, Baumann K, Beyer D, Kohls EB, Lausen K, Hanker L, Holtrich U, Becker S, Karn T.

Breast Cancer Res Treat. 2015 Aug;152(3):667-73. doi: 10.1007/s10549-015-3491-3. Epub 2015 Jul 21.

PMID:
26195120
19.

Predictive role of HER2/neu, topoisomerase-II-alpha, and tissue inhibitor of metalloproteinases (TIMP-1) for response to adjuvant taxane-based chemotherapy in patients with intermediate-risk breast cancer: results from the WSG-AGO EC-Doc trial.

Erber R, Gluz O, Brünner N, Kreipe HH, Pelz E, Kates R, Bartels A, Huober J, Mohrmann S, Moustafa Z, Liedtke C, Möbus V, Augustin D, Thomssen C, Jänicke F, Kiechle M, Kuhn W, Nitz U, Harbeck N, Hartmann A.

Breast Cancer Res Treat. 2015 Apr;150(2):279-88. doi: 10.1007/s10549-015-3310-x. Epub 2015 Feb 28.

PMID:
25721604
20.

Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression.

Nitz U, Gluz O, Huober J, Kreipe HH, Kates RE, Hartmann A, Erber R, Moustafa Z, Scholz M, Lisboa B, Mohrmann S, Möbus V, Augustin D, Hoffmann G, Weiss E, Böhmer S, Kreienberg R, Du Bois A, Sattler D, Thomssen C, Kiechle M, Jänicke F, Wallwiener D, Harbeck N, Kuhn W.

Ann Oncol. 2014 Aug;25(8):1551-7. doi: 10.1093/annonc/mdu186. Epub 2014 May 14. Erratum in: Ann Oncol. 2017 Nov 1;28(11):2899.

PMID:
24827128
21.

HER2 Dimerization Inhibitor Pertuzumab - Mode of Action and Clinical Data in Breast Cancer.

Harbeck N, Beckmann MW, Rody A, Schneeweiss A, Müller V, Fehm T, Marschner N, Gluz O, Schrader I, Heinrich G, Untch M, Jackisch C.

Breast Care (Basel). 2013 Mar;8(1):49-55. doi: 10.1159/000346837. Review.

22.

Genomic profiling in luminal breast cancer.

Gluz O, Hofmann D, Würstlein R, Liedtke C, Nitz U, Harbeck N.

Breast Care (Basel). 2013 Dec;8(6):414-22. doi: 10.1159/000357535. Review.

23.

Association of HER2 Overexpression and Prognosis in Small (T1N0) Primary Breast Cancers.

Rom J, Schumacher C, Gluz O, Höfler J, Eidt S, Domschke C, Marmé F, Nitz U, Sohn C, Schneeweiss A.

Breast Care (Basel). 2013 Jun;8(3):208-14. doi: 10.1159/000352094.

24.

Final results from the prospective phase III WSG-ARA trial: impact of adjuvant darbepoetin alfa on event-free survival in early breast cancer.

Nitz U, Gluz O, Zuna I, Oberhoff C, Reimer T, Schumacher C, Hackmann J, Warm M, Uleer C, Runde V, Dünnebacke J, Belzl N, Augustin D, Kates RE, Harbeck N; West German Study Group.

Ann Oncol. 2014 Jan;25(1):75-80. doi: 10.1093/annonc/mdt505.

PMID:
24356620
26.

Lumpectomy versus mastopexy--a post-surgery patient survey.

Eichler C, Kolsch M, Sauerwald A, Bach A, Gluz O, Warm M.

Anticancer Res. 2013 Feb;33(2):731-6.

PMID:
23393375
27.

Recognition and handling of discordant negative human epidermal growth factor receptor 2 classification by Oncotype DX in patients with breast cancer.

Christgen M, Harbeck N, Gluz O, Nitz U, Kreipe HH.

J Clin Oncol. 2012 Sep 10;30(26):3313-4; author reply 3314-5. doi: 10.1200/JCO.2012.42.1990. Epub 2012 May 29. No abstract available.

PMID:
22649153
28.

Intraoperative ultrasound: improved resection rates in breast-conserving surgery.

Eichler C, Hübbel A, Zarghooni V, Thomas A, Gluz O, Stoff-Khalili M, Warm M.

Anticancer Res. 2012 Mar;32(3):1051-6.

PMID:
22399631
29.

Tumor angiogenesis as prognostic and predictive marker for chemotherapy dose-intensification efficacy in high-risk breast cancer patients within the WSG AM-01 trial.

Gluz O, Wild P, Liedtke C, Kates R, Mendrik H, Ehm E, Artinger V, Diallo-Danebrock R, Ting E, Mohrmann S, Poremba C, Harbeck N, Nitz U, Hartmann A, Gaumann A.

Breast Cancer Res Treat. 2011 Apr;126(3):643-51. doi: 10.1007/s10549-011-1377-6. Epub 2011 Feb 12.

PMID:
21318601
30.

Personalized treatment of early-stage breast cancer: present concepts and future directions.

Harbeck N, Salem M, Nitz U, Gluz O, Liedtke C.

Cancer Treat Rev. 2010 Dec;36(8):584-94. doi: 10.1016/j.ctrv.2010.04.007. Epub 2010 Jun 2. Review.

PMID:
20554119
31.

Y-box-binding protein YB-1 identifies high-risk patients with primary breast cancer benefiting from rapidly cycled tandem high-dose adjuvant chemotherapy.

Gluz O, Mengele K, Schmitt M, Kates R, Diallo-Danebrock R, Neff F, Royer HD, Eckstein N, Mohrmann S, Ting E, Kiechle M, Poremba C, Nitz U, Harbeck N.

J Clin Oncol. 2009 Dec 20;27(36):6144-51. doi: 10.1200/JCO.2008.19.6261. Epub 2009 Nov 9.

PMID:
19901122
32.

Triple-negative breast cancer--current status and future directions.

Gluz O, Liedtke C, Gottschalk N, Pusztai L, Nitz U, Harbeck N.

Ann Oncol. 2009 Dec;20(12):1913-27. doi: 10.1093/annonc/mdp492. Epub 2009 Nov 9. Review.

PMID:
19901010
33.

Nuclear karyopherin alpha2 expression predicts poor survival in patients with advanced breast cancer irrespective of treatment intensity.

Gluz O, Wild P, Meiler R, Diallo-Danebrock R, Ting E, Mohrmann S, Schuett G, Dahl E, Fuchs T, Herr A, Gaumann A, Frick M, Poremba C, Nitz UA, Hartmann A.

Int J Cancer. 2008 Sep 15;123(6):1433-8. doi: 10.1002/ijc.23628.

34.

[Prognostic and predictive impact of protein expression profiling in high risk breast cancer patients treated with high-dose chemotherapy].

Diallo-Danebrock R, Ting E, Gluz O, Herr A, Mohrmann S, Geddert H, Gabbert HE, Nitz U, Poremba C.

Verh Dtsch Ges Pathol. 2007;91:187-96. German.

PMID:
18314614
35.

Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial.

Gluz O, Nitz UA, Harbeck N, Ting E, Kates R, Herr A, Lindemann W, Jackisch C, Berdel WE, Kirchner H, Metzner B, Werner F, Schütt G, Frick M, Poremba C, Diallo-Danebrock R, Mohrmann S; West German Study Group.

Ann Oncol. 2008 May;19(5):861-70. doi: 10.1093/annonc/mdm551. Epub 2008 Jan 3.

PMID:
18174609
36.

C-kit expression in high-risk breast cancer subgroup treated with high-dose or conventional dose-dense chemotherapy.

Diallo R, Ting E, Gluz O, Herr A, Schütt G, Geddert H, Mohrmann S, Gabbert HE, Nitz U, Poremba C.

Verh Dtsch Ges Pathol. 2006;90:177-85.

PMID:
17867595
37.

Protein expression profiling in high-risk breast cancer patients treated with high-dose or conventional dose-dense chemotherapy.

Diallo-Danebrock R, Ting E, Gluz O, Herr A, Mohrmann S, Geddert H, Rody A, Schaefer KL, Baldus SE, Hartmann A, Wild PJ, Burson M, Gabbert HE, Nitz U, Poremba C.

Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):488-97.

38.

Randomized trial of single compared with tandem high-dose chemotherapy followed by autologous stem-cell transplantation in patients with chemotherapy-sensitive metastatic breast cancer.

Kröger N, Frick M, Gluz O, Mohrmann S, Metzner B, Jackisch C, Ko Y, Lindemann HW, Meier CR, Lohrmann HP, Ruffert U, Hänel M, Bodenstein H, Neubauer A, Ehninger G, Wolf HH, Kolbe K, Burock K, Zander AR, Nitz U.

J Clin Oncol. 2006 Aug 20;24(24):3919-26.

PMID:
16921043

Supplemental Content

Support Center